Top Markets
#1 Ontology Gas Ontology Gas +26.68%
#2 Verus Coin Verus Coin +22.51%
#3 EXOD EXOD +22.08%
#4 ETHGas ETHGas +17.69%
#5 Status Status +17.53%
#6 Geodnet Geodnet +14.38%
#7 Derive Derive +12.51%
#8 Curve DAO Curve DAO +11.86%
#9 The Black Bull The Black Bull +10.06%
#10 Anvil Anvil +9.81%
Coin of the day
Ontology Gas Ontology Gas
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Vicapsys Life Sciences, Inc. Vicapsys Life Sciences, Inc.

Vicapsys Life Sciences, Inc.

VICP
Clasificación en acciones #25715
Vicapsys Life Sciences, Inc. is primarily focused on bringing its exclusive... Vicapsys Life Sciences, Inc. is primarily focused on bringing its exclusive VICAPSYN product to market, guiding it through development and commercialization. This product's intended application is within the field of transplantation, specifically for various transplant therapies and associated stem-cell uses. Additionally, the company is advancing the development of VYBRIN, a compound based on CXCL12. VYBRIN is being investigated for multiple purposes: preventing the formation of post-surgical adhesions following abdominal operations, coating implantable medical devices and other implants to inhibit fibrosis, and promoting wound healing, with a particular emphasis on diabetic ulcers. The firm, originally incorporated in 1997, transitioned its name from Phage Therapeutics International, Inc. to Vicapsys Life Sciences, Inc. in September 2017. Its operations are headquartered in Suwanee, Georgia.
Precio por acción
$1.45
Última sincronización: 2026-08-19
Capitalización bursátil
$46.94M
Cambio (1 día)
0.00%
Cambio (1 año)
-18.08%
País
US
Comercio Vicapsys Life Sciences, Inc. (VICP)

Categoría

Healthcare
Ganancias de Vicapsys Life Sciences, Inc. (VICP)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Vicapsys Life Sciences, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Vicapsys Life Sciences, Inc. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US